Bone disease after renal transplantation by Kunzendorf, U et al.
University of Zurich





Bone disease after renal transplantation
Kunzendorf, U; Krämer, B K; Arns, W; Braun, J; Grossmann, J; Pietruck, F;
Schmidt-Gayk, H; Schwarz, A; Ziegler, E; Sperschneider, H; Wüthrich, R P;
Nonnast-Daniel, B; Schindler, R; Renders, L
Kunzendorf, U; Krämer, B K; Arns, W; Braun, J; Grossmann, J; Pietruck, F; Schmidt-Gayk, H; Schwarz, A;
Ziegler, E; Sperschneider, H; Wüthrich, R P; Nonnast-Daniel, B; Schindler, R; Renders, L (2008). Bone disease
after renal transplantation. Nephrology Dialysis Transplantation, 23(2):450-458.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Nephrology Dialysis Transplantation 2008, 23(2):450-458.
Kunzendorf, U; Krämer, B K; Arns, W; Braun, J; Grossmann, J; Pietruck, F; Schmidt-Gayk, H; Schwarz, A;
Ziegler, E; Sperschneider, H; Wüthrich, R P; Nonnast-Daniel, B; Schindler, R; Renders, L (2008). Bone disease
after renal transplantation. Nephrology Dialysis Transplantation, 23(2):450-458.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Nephrology Dialysis Transplantation 2008, 23(2):450-458.
Nephrol Dial Transplant (2008) 23: 450–458
doi: 10.1093/ndt/gfm816
Advance Access publication 1 December 2007
Editorial Review
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Introduction
Because of increasing life expectancy after renal transplan-
tation, the prevention of long-term complications, such as
bone disease, has become an essential part of post-renal-
transplant care. Bone disease is one of the possible long-
term complications that can significantly influence quality
of life. Compared to members of the normal population of
the same age, the fracture rate in renal transplant patients is
four times higher. In addition, there is a risk for avascular
bone necrosis after transplantation, which mainly affects
weight-bearing bone structures, such as femoral heads, and
as a rule, can only be treated by hip replacement with endo-
prosthesis. Histological evidence of abnormal bone struc-
ture, osteodystrophy and osteopaenia is already present
shortly after transplantation in almost all transplant recipi-
ents [1].
Bone disease after renal transplantation differs frombone
disease after transplantation of non-renal solid organs. Bone
disease after non-renal solid organs is often similar to
steroid-induced osteoporosis. In addition, accessory factors
such as low 25-hydrolylase activity in liver graft recipients
may lead to osteomalacia. However, after renal transplanta-
tion, bone disease is in large part due to pre-existing bone
damage acquired during dialysis therapy and renal insuffi-
ciency and because of factors that affect the bone to vary-
ing degrees after successful renal transplantation. Apart
from immunosuppressive agents, metabolic factors such
as hyperphosphaturia, persistent hyperparathyroidism with
hypercalcaemia, disturbances to the acid–base balance and
hypomagnesaemia also play an important role.
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Renal bone disease before transplantation has once again
become the object of attention because of our better under-
standing of important pathogenic mechanisms underlying
hyperparathyroidism and its regulation, bone metabolism
and the impact of hyperphosphataemia and hypercalcaemia
on cardiovascular mortality. In addition, new drugs have
been developed, such as the calcium-free phosphate binders
sevelamer and lanthanum carbonate, or the calcimimetic
drug cinacalcet, which have broadened the range of avail-
able therapeutic options. Moreover, these pharmacological
approaches provide new understanding of and therapy for
bone disease after successful renal transplantation. These
aspects will be described below.
Clinical importance of bone disease after renal
transplantation
A retrospective analysis of 1572 kidney graft recipients
showed a fracture incidence of 19.1%within an average ob-
servation period of 6.5 years, with 6.4% of all patients suf-
fering multiple fractures [2]. After the exclusion of malle-
olar fractures (8.3%) and avascular bone necroses (5.0%),
the cumulative fracture incidence was 12.0% after 5 years,
18.5% after 10 years and 23.0% after 15 years. Over 16%
of the patients had deformations of the spine and vertebral
fractures inappropriate for the force causing the injury [3].
Consequently, the long-term risk of fracture far exceeds
that of the normal population, which is ∼1% in women
65 years of age and below and ∼6–10% in 75-year-old
women [4]. What is the risk of fracture for patients on the
waiting list for transplantation compared to renal transplant
recipients? Retrospectively, 101 039 patients on the waiting
list for renal transplantation were evaluated [5]. Of those,
41 095 (40.7%) had never received a transplant and could
thus be compared with 59 944 (59.3%) transplant recipi-
ents. The mean follow-up duration was 2.98 years. In total,
971 patients had a hip fracture. In dialysis patients, the frac-
ture rate was 2.9 fractures per 1000 patient-years versus 3.3
C© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Prevention of bone disease after renal transplantation 451
Fig. 1. Calculated relative risk of fractures after renal transplantation
in comparison with patients on the waiting list for renal transplantation
(the interrupted line marks the 95% confidence interval) (Reprint with
permission from American Medical Association [5]).
fractures in transplant recipients. Consequently, their risk
was 34% higher. However, the risk of fracture in transplant
recipients compared to patients on the waiting list decreases
continuously over time. In the first 6months after transplan-
tation, the relative risk among transplant recipients is 1.34
times higher, but it decreases by 1% per month, so after
∼630 days, a similar risk is found in both groups. After
this point, the risk of fracture for transplant recipients falls
below that of patients from the waiting list (Figure 1).
To answer the question of how to avoid fractures and
which type of prophylaxis is the most adequate, the patho-
genesis of bone disease after renal transplantation will be
reviewed. Special attention will be paid to the fact that the
individual components of bone disease change over time.
From these considerations, the appropriateness and timing
of the respective therapies can be derived.
Because the aim of an optimal prophylaxis is to reduce
the fracture rate after transplantation, therapeutic interven-
tions have to be proven in prospective, randomized, blinded
studies. Most published studies cannot answer this ques-
tion, either because of insufficient duration or number of
patients. Studies based on the examination of histological
changes in bone are also rare. Therefore, change in bone
density is almost always chosen as a surrogate parameter,
even though change in bone density does not provide any
information on the architecture or histology of bone. Al-
though stability of bone density or even an increase in bone
density represents a good surrogate parameter for an ef-
fective prophylaxis of osteoporotic fractures [6], this does
not fully apply to situations present after transplantation.
Renal transplant recipients with abnormally low bone den-
sity may have a low fracture rate; more than one-third of
the patients with fractures showed no signs of osteoporosis
in bone density measurements [7,8]. Nonetheless, changes
in bone density remain the standard parameter for most
studies in regard to the efficacy of various prophylactic
measures.
Pathogenesis of bone disease after transplantation
Bone disease in transplant recipients is based on pre-
existing damage to the bone acquired during the period
Fig. 2. Factors causing bone disease after transplantation [5,68].
of renal insufficiency, damage to the bone starting in the
period of transplantation and modulating influences inde-
pendent of renal disease or renal transplantation (Figure 2).
Important factors comparatively independent of renal
disease will not be discussed here in detail, even though
they are significant. Some of these factors, such as smok-
ing or physical inactivity, should be actively considered as
a part of the preventive actions.
The starting point for bone disease after transplantation
is the period during pre-terminal renal insufficiency and re-
nal replacement therapy. The different factors contributing
to bone disease, including secondary hyperparathyroidism
accompanied by hyperphosphataemia, decreased calcitriol
concentrations and variable calcium concentrations can be
identified to various degrees in biopsies of patients imme-
diately after renal transplantation, thus reflecting the ‘base-
line’ before other factors that affect the bone after transplan-
tation have time to produce detectable changes. In a study
on the effectiveness of bisphosphonates, 50% of the biop-
sies taken from patients immediately after transplantation
showed bone with high turnover, with the dominant pic-
ture being osteitis fibrosa, while∼30% had adynamic bone
and ∼20% showed a mixed picture [9]. This distribution of
bone disease shows geographic variation and is primarily
subject to the therapeutic regimen that was in place prior to
transplantation.
Development of bone disease after renal
transplantation
Immediately after transplantation and along with the start
of transplant function, many factors, which are responsible
for the development of renal osteodystrophy, undergo some
fundamental changes. Often as early as during the first post-
transplant week, hyperphosphataemia-–one of the earliest
factors to develop-–turns into hypophosphataemia because
of marked hyperphosphaturia. The increase in parathyroid
hormone excretion, which becomes autonomous over time,
452 U. Kunzendorf et al.
continues and calcitriol concentration, which varies widely
in renal transplant recipients immediately after the proce-
dure, is often accompanied by episodes of hypercalcaemia.
To detect the developing changes at an early stage, monitor-
ing according to the K/DOQI guidelines is recommended
[10].
In addition to these factors, immunosuppressive regi-
mens, especially the use of steroids, play a decisive role.
Because all the above-mentioned factors act simultane-
ously on the bone-–which is already affected by a wide
variety of pre-existing pathological changes-–while simul-
taneously interacting with each other, bone disease after
transplantation manifests as a complex condition. For the
prophylactic or therapeutic treatment of bone disease af-
ter transplantation in an individualized, targeted and ra-
tional manner, it is helpful to look at the individual fac-
tors acting on the bone after transplantation in greater
detail.
Importance of hyperparathyroidism for the development of
bone disease
The lack of guidelines to define what is considered a ‘nor-
mal’ PTH concentration in kidney graft recipients is due
to the lack of well-controlled studies that correlate PTH
concentrations with alterations of the bone after transplan-
tation. Most often, a target PTH concentration adjusted to
the kidney function as in other patients with kidney diseases
has been used. One must be aware of the possibility that
this may not adequately reflect the complex situation in the
transplant setting.
Parathyroid function after renal transplantation has been
evaluated in a number of studies. In about two-thirds of
renal transplant recipients, increased parathyroid hormone
levels are found immediately after transplantation [11]. The
parathyroid hormone concentration falls by ∼50% within
the first 2 weeks, followed by a more gradual decrease; as
a result, approximately half of the renal transplant recip-
ients with good transplant function have normal parathy-
roid hormone levels after about 3 months, and after 1 year,
only between 10 and 50% of patients suffer from hyper-
parathyroidism [12]. In the further course, there is only
a slight additional decrease in the hyperparathyroidism
rate; 21% of the transplant recipients still show abnor-
mally high levels of parathyroid hormone up to 15 years
after transplantation [13]. Hyperparathyroidism is associ-
ated with a high percentage of hypercalcaemic episodes.
During a post-renal-transplant follow-up period of up to
5 years, hypercalcaemic episodes were found in 46% of
cases after 1 year, 40% after 3 years and 24% after 5
years [11]. The progression from secondary to tertiary hy-
perparathyroidism, i.e. the form that no longer responds
to the normalization of calcium, phosphate and calcitriol,
is promoted by both prolonged periods of hyperphos-
phataemia and delayed calcitriol therapy prior to transplan-
tation, and is very difficult to reverse after transplantation.
Tertiary hyperparathyroidism is based on somaticmutations
in individual parathyroid gland cells finally resulting in
clonal expansion and adenoma formation, which are asso-
ciated with a depressed expression of calcium-sensing and
vitamin D receptors [14]. Finally, impaired renal trans-
plant function with far below normal performance in many
patients is another factor that prevents normalization of
hyperparathyroidism.
The primary target of parathyroid hormone is osteoblasts.
Osteoblasts, but not osteoclasts, express PTH receptors.
PTH increases the number, activity and lifespan of os-
teoblasts and also protects osteoblasts against steroid-
induced apoptosis [15]. The activation of osteoclasts by
parathyroid hormone is an indirect effect based on cell–
cell contacts with osteoblast-like cells. In addition, increas-
ing evidence suggests a binding of intact PTH, but not
PTH 1–34 to osteoclasts, possibly through the novel PTH
receptors (CPTHRs) resulting in an increased osteoclast
activity and number [16–18]. In physiological concentra-
tions, PTH leads to increased bone remodelling and an
increase in trabecular bone volume compared to cortical
bone.
In summary, bone damage caused by chronic hyper-
parathyroidism most closely resembles osteitis fibrosa.
However, hyperparathyroidism and hypercalcaemia also
correlate with interstitial microcalcifications in the trans-
plant. Interstitial microcalcifications are, in turn, an in-
dicator of poor prognosis regarding long-term func-
tion [19]. Thus, apart from bone disease, pathological
changes in extraosseous organs also have to be taken into
consideration.
Importance of hypophosphataemia for the development of
bone disease
The development of hypophosphataemia as a result of
hyperphosphaturia soon after renal transplantation is a
common complication, observed in more than 90% of
transplant patients [20]. Although the serum phosphate
concentration normalizes in most patients after 1 year,
this does not apply to hyperphosphaturia; increased frac-
tional phosphate excretion can still be detected after 1 year
[21]. Even hypophosphataemia can be detected up to 10
years after transplantation in some patients [22]. This hy-
pophosphataemia is the result of impaired reabsorption
of phosphate in the proximal tubule, where up to 80%
of the filtered phosphate is reabsorbed. Tubular reabsorp-
tion can be decreased by various factors, including: hyper-
parathyroidism, calcitriol deficiency, corticosteroid ther-
apy, phosphatonins (e.g. FGF23), hormones (e.g. insulin,
thyroid hormones, glucagons), cytokines (e.g. insulin-like
growth factor I, EGF), phosphate-rich diet, and metabolic
acidosis.
High parathyroid hormone levels can reduce phosphate
reabsorption in the proximal tubule from 80 to 20%. Cer-
tainly, persistent hyperparathyroidism is not the only factor.
In patients with normal kidneys, a primary hyperparathy-
roidism with very high parathyroid hormone levels is often
only associatedwithmild hypophosphataemia or none at all.
The underlying mechanism may also be the increased pro-
duction of calcitriol as a result of the parathyroid hormone-
induced stimulation of renal 1α-hydroxylase because cal-
citriol can increase the activity of the Na/Pi cotransporter,
both in the intestines and in the proximal tubule [23]. In
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renal transplant recipients, however, low calcitriol levels
are often found despite normal 25-OH-D3-concentrations
and persistent hyperparathyroidism [24], which in-
creases the hypophosphataemia. That parathyroid hormone
cannot be the only factor responsible for the development of
hypophosphataemia is further demonstrated by renal trans-
plant recipients who develop severe hypophosphataemia
in the presence of normal parathyroid hormone concen-
trations or after parathyroidectomy and normal calcitriol
concentrations [21]. Apart from steroids, which inhibit
the Na/Pi cotransporter independently of parathyroid hor-
mone and vitamin D23, phosphatonins, such as FGF23,
seem to play a significant role in the development of
hypophosphataemia. The serum concentrations of FGF23
immediately after renal transplantation are markedly in-
creased and drop off gradually over a period of days
and weeks to a level that is still above the reference
range for healthy controls [25].While FGF23 concentration
among controls is directly correlated with serum phosphate
concentration-–a finding also confirmed in animal exper-
iments using phosphate infusions–an inverse correlation
is found among hypophosphataemic transplant recipients.
Pre-transplant FGF23 concentrations are the strongest pre-
dictor of the post-transplant FGF23 concentration indepen-
dently of the post-transplant serum phosphate. Recently,
it has been suggested to call these findings ‘tertiary hy-
perphosphatoninism’ [25,26]. In addition to direct effects
of FGF23 on phosphate regulation, FGF23 also inhibits
the 1α-hydroxylase activity resulting in an impaired pro-
duction of calcitriol that may accentuate hypophospatemia
[27]. That phosphatonins play a significant role in
phosphate regulation is demonstrated by various genetic
models and disorders [28,29]. Hypophosphataemia is asso-
ciated with increased osteoblast apoptosis, diminished os-
teoblast activity and decreased osteoblastogenesis—factors
also promoting the development of osteomalacia after
transplantation.
In summary, hypophosphataemia causes changes that
most closely resemble osteomalacia.
Importance of immunosuppressive agents on the
development of bone disease
The standard immunosuppressive regimen after renal trans-
plantation consists of a calcineurin inhibitor (cyclosporine
or tacrolimus), mycophenolate or an mTOR inhibitor, such
as rapamycin or everolimus, and steroids. An antibody for
induction or rejection therapy may be added to this im-
munosuppressive regimen. No study data on the effects
of antibodies on bone is available. Likewise, the effect
of mycophenolic acid and mTOR inhibitors is poorly in-
vestigated. Rapamycin may contribute to the develop-
ment of hypophosphataemic osteomalacia by increasing
hyperphosphaturia. For calcineurin inhibitors, especially
cyclosporine, data from various in vitro and in vivo studies
have been published. In rat models, the administration of
cyclosporine resulted in bone loss, especially of the tra-
becular bone, with increased bone remodelling and high
osteocalcin levels [30,31]. Studies in transplant recipients
are hampered by the fact that it is virtually impossible to
exclude the influences of other factors on the bone that act
in addition to cyclosporine. Consequently, the significance
of bone injury caused by cyclosporine remains uncertain
in patients. However, bone loss is not observed in steroid-
free patients treated with cyclosporine; thus, cyclosporine’s
contribution to bone disease appears to be of lesser
significance [32,33]. Tacrolimus also causes bone loss
in rats and again, the trabecular bone is most af-
fected [31]. In a direct comparison between cyclosporine
and tacrolimus in liver transplant recipients, patients
treated with tacrolimus showed a higher degree of bone
loss [34].
Unlike the immunosuppressive agents mentioned so far,
a large number of studies have established that steroids
cause bone density loss and induce both osteoporosis and
bone necroses, which correspond to an increased fracture
rate. The bone mass-decreasing effect of steroids is the re-
sult of reduced bone formation along with concomitantly
increased bone resorption. (1) Reduced bone formation:
as in a number of other cell types, steroids induce apop-
tosis in osteoblasts and osteocytes and inhibit osteoblas-
togenesis by blocking the division and differentiation of
osteoblasts [35]. In addition, they inhibit the generation of
several proteins essential for bone formation, such as col-
lagen type I, insulin-like growth factor, TGF-β and bone
matrix proteins, and interfere with central elements of cell
activation, e.g. by inhibiting the activation of NFκ-B. In-
direct steroid effects that impair bone formation are medi-
ated by a number of hormones; steroids, for example in-
hibit testosterone synthesis [36]. Finally, steroid therapy
leads to serum calcium depletion directly and indepen-
dently of vitamin D by reducing intestinal calcium reab-
sorption through the mobilization of calcium from bone
and the inhibition of tubular calcium reabsorption by the
kidneys [37,38]. (2) Increased bone resorption: in compar-
ison to decreased bone formation, increased bone resorp-
tion is of less significance. The increase in bone resorp-
tion is directly caused by the stimulation of osteoclast-like
cells [39] and indirectly by the steroid-induced inhibition of
androgen, oestrogen and gonadotropin synthesis. Steroids
can increase parathyroid hormone synthesis, which again
results in increased bone remodelling and resorption, ei-
ther directly or indirectly through steroid-induced calcium
depletion.
In summary, steroid-based immunosuppression triggers
complex bone changes that most closely resemble osteo-
porosis.
Prevention of and therapy for bone disease after
transplantation
On a background of pre-existing bone damage, immuno-
suppressive agents, especially high steroid doses during the
first 3–6 months and, in a large proportion of the patient
population, both newly developing hypophosphataemia and
the persisting hyperparathyroidism all affect the bone.
Guidelines for the prevention of post-transplant bone dis-
ease have been published by various transplantation soci-
eties.
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Table 1. Treatment and prevention of bone disease after renal transplantation according to the European Best Practice Guidelines [69]
Vitamin Da Calcitriol 0.25–0.5 µg/day or cholecalciferol 600 units/day
Calciumb 1000 mg/day, or 1500 mg/day in post-menopausal women
Bisphosphonates In patients with an increased fracture riskb and good transplant function GFR > 60 ml/min
• Avoidance of loop diuretics








• Use of calcitonin
aHypercalciaemia is a contraindication. Consider, calcitriol may further impair a deteriorated kidney function [70].
bFactors associatedwith increased fracture risk include: severe osteoporosis, previous fractures, diabetesmellitus, combined kidney–pancreas
transplantation and post-menopausal women.
Guidelines for the prevention of bone disease after kidney
transplantation
For the prevention of bone injury in the early phase af-
ter transplantation and during steroid therapy, guidelines
have been issued, which will be described in the follow-
ing section (Table 1). The use of vitamin D and calcium is
generally recommended in the absence of contraindications.
Corresponding recommendations are made in the K/DOQI
guidelines. Because hypercalcaemia is a contraindication,
this type of prophylaxis is not suitable for all patients.While
the use of calcitriol consistently prevented bone density loss
compared to placebo, this is not the case for cholecalciferol
[40,41].
The use of bisphosphonates is limited to the high-risk
group (Table 1). Likewise, the K/DOQI guidelines restrict
therapies using bisphosphonates with recommended use
starting at a T-score of >−2 SD [10]. Various bisphos-
phonates have proven their efficacy in studies, and some
examples are provided in Table 2.
A meta-analysis showed that a therapy consisting of
calcium, vitamin D or bisphosphonates alone significantly
reduced bone density loss. A combination of vitamin D and
calcium was superior to calcium alone [40].
Bisphosphonates directly inhibit osteoclast activity [42].
However, this approach is associated with the risk that al-
though bone density loss is prevented, the bone remod-
elling process almost comes to a standstill such that bis-
phosphonate treatment of bone disease results in adynamic
bone [9,43]. For this reason, their use is limited to risk
groups. In addition, there are several reports regarding
bisphosphonate-associated osteonecrosis after long-term
treatment [44].
A significant number of studies were incorporated in
the recommendations of transplantation societies, but these
studies were not end-point studies measuring fracture rate.
In these studies, the efficacy of a preventative therapy was
determined bymissing or retarded decrease in bonemineral
density.
The European Best Practice Guidelines recommend
the initiation of treatment for hypophosphataemia in the
presence of ‘severe hypophosphataemia’; the K/DOQI
guideline recommends treatment initiation below 0.81
mmol/l [10,45]. Because hypophosphataemia therapy is a
common condition associated with specific clinical chal-
lenges, it will be discussed in detail in the following section.
This also applies to the treatment of hyperparathyroidism
after transplantation.
Hypophosphataemia treatment
The effects of such guideline-based therapies on the bone
and extraosseous organs, such as the transplant and the car-
diovascular system, have not yet been studied adequately. In
hypophosphataemic transplant recipients, parathyroid hor-
mone production is induced by the administration of phos-
phate, which results in the worsening of any pre-existing
hyperparathyroidism, with associatedmild decreases in cal-
citriol concentrations and serum calcium concentrations
[46]. With the aggravation of hyperparathyroidism, the
serum calcium–phosphate product increases, and the addi-
tional inhibition of phosphate reabsorption in the proximal
tubule exacerbates the hyperphosphaturia. The hyperphos-
phaturia is even further augmented because the administra-
tion of phosphate also results in an increase in serumFGF23
levels [47]. The role of the higher calcium/phosphate ex-
cretion and increased calcium–phosphate product remains
to be investigated in randomized studies in renal trans-
plant recipients. However, this constellation is associated
with an increased mortality rate among haemodialysis
patients [48]. In protocol biopsies, the detection of in-
terstitial microcalcifications early in the course is asso-
ciated with a significantly poorer prognosis [19]. These
patients also showed increased serum parathyroid hormone
concentrations. Consequently, the call for a rigorous ther-
apy for hypophosphataemia, as in the K/DOQI guidelines,
should be treated with caution. In symptom-free patients,
we are very reluctant to administer phosphate to treat hy-
pophosphataemia. Whether dipyridamol, which increases
reabsorption of phosphate in the proximal tubule even in
transplanted kidneys, may be considered as an alternative
treatment option needs to be evaluated in larger studies
[49].
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Table 2. Dosage of selected bisphosphonates after renal transplantation
Active ingredient Dosage Reference
Pamidronate Aredia
R©
60 mg i.v. peri-operatively (p.o.) [9]
30 mg i.v. after Months 1, 2, 3 and 6
Ibandronate Bondronat
R©
1 mg i.v. preoperatively [71]
2 mg i.v. after Months 3, 6 and 9
Alendronate Fosamax
R©
5–10 mg/day p.o. [72]
70 mg/1× weekly p.o.
Risedronate Actonel
R©
5 mg p.o./day from Month 2 [73]
Note: To date, the use of bisphosphonates for the prophylactic treatment of osteoporosis after transplantation has not been approved in Germany and
other countries.
Table 3. Success of cinacalcet treatment of persistent hyperparathyroidism after renal transplantation
Number of patients treated Parathyroid hormone (pg/ml) Calcium (mmol/l) Phosphate (mmol/l) Creatinine (µmol/l) Reference
(n = 14) Day 0 300 2.7 1.0 140 [74]
Month 3 150 2.4 1.1a 148
(n = 11) Day 0 176 2.73 0.8 118 [75]
Week 10 135 2.42 1.0 125
(n = 9) Day 0 171 2.75 0.70 49.8 [76]
Month 6 134 2.44 0.77 51.3
(n = 10) Day 0 721 2.75 0.87 106 [77]
Month 6 331 2.4 1.03 unavailable
(n = 18) Day 0 627 2.55 1.00 159.1 [78]
Month 6 365 2.35 1.13 176.8
aTwo additional patients had a mild hyperphosphataemia of 1.65 mol/l and 1.77 mol/l, respectively.
Hyperparathyroidism therapy after transplantation
Successful renal transplantation eliminates a number of ae-
tiological factors that lead to the development of hyper-
parathyroidism during renal insufficiency. As already men-
tioned above, parathyroid function tends to normalize over
time in many patients. However, this normalization process
may be very slow, especially in cases of suboptimal trans-
plant function. In particular, during the early post-transplant
phase, there is a need to take action for several reasons. (1)
After renal transplantation, the early phase is characterized
by a particularly high rate of hypercalcaemic episodes be-
cause the persisting hyperparathyroidism that is frequently
accompanied by normalized calcitriol production and the
resorption of extraosseous calcium–phosphate deposits af-
ter the normalization of serum phosphate levels [50]. These
hypercalcaemias have a negative impact on the whole or-
ganism as well as on the transplant. (2) The management
of bone disease in renal transplant recipients with hyper-
parathyroidism poses a particular challenge to the clini-
cian because (a) the proven prophylactic therapy of the
post-transplant bone disease with vitamin D and calcium
supplementation is contraindicated by the hypercalcaemic
episodes and (b) bisphosphonates inhibit osteoclastic bone
resorption by accumulating in the bone, especially in areas
of bone resorption. They reduce the number of osteoclasts
by inhibiting the division and differentiation of osteoclastic
precursors and by the induction of apoptosis in mature os-
teoclasts. Although the plasma half-life of bisphosphonates
is in the range of 30 min because of rapid renal elimination
in the presence of normal renal function, bisphosphonates
are deposited in the bone for long periods of time, even
for life. If parathyroid hormone levels fail to normalize and
a parathyroidectomy becomes necessary at a later stage,
this intervention will be associated with the long-term risk
of inducing the development of adynamic bone. (3) In up
to 70% of the kidneys, the hyperparathyroidism is associ-
ated with interstitial calcifications. These microcalcifica-
tions predict a poor long-term prognosis for the transplant
[19,51]. Therefore, it is already necessary at an early stage
after transplantation to treat hyperparathyroidism. Parathy-
roidectomy and therapy with calcimimetics are available
for this purpose.
Parathyroidectomy
Apart from immediate intraoperative and perioperative
complications including hypocalcaemia, parathyroidec-
tomy is associated with the risk of aggravating the bone
disease and causing partial transplant function loss. As de-
scribed above, parathyroid hormone plays a central role in
bone formation because of its effect on osteoblasts. Parathy-
roid hormone can partially counteract the pro-apoptotic ef-
fect of steroids on osteoblasts. Recombinant parathyroid
hormone has become an integral part of the management of
osteoporosis with histologically confirmed bone formation
and a significantly reduced fracture rate [52,53]. Conse-
quently, in the critical phase of most severe bone damage
[1] and with the highest fracture risk [5], subtotal or total
parathyroidectomy may result in the loss of the protective
effect of the parathyroid hormone by an uncontrolled de-
crease or complete loss of parathyroid hormone production.
Finally, parathyroidectomy may have a negative ef-
fect on transplant function. On average, patients with
hyperparathyroidism have significantly better transplant
function [54]. As a result, increases in serum creatinine
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concentrations by up to 30% are observed after parathy-
roidectomy [55]. The mechanism underlying this deterio-
ration is not fully understood. While some studies found
an increased rate of renal graft rejections after parathy-
roidectomy, evidence from other studies does not support
this finding. The extent of the parathyroid hormone de-
crease correlates with the extent of the creatinine increase
[51]. Consequently, functional changes may underlie this
observation. In fact, parathyroid hormone can directly di-
late pre-glomerular arterioles in isolated perfused kidneys
[56]. In rat models as well as in humans, however, parathy-
roid hormone infusion increases GFR and diuresis without
changing the filtration fraction [57,58]. The importance
of parathyroidectomy for long-term renal graft function
remains unclear. Studies comparing long-term renal graft
survival in patients after parathyroidectomy with those of
patients without parathyroidectomy provide conflicting ev-
idence with some research showing significantly poorer
long-term survival for renal grafts while in other studies,
no significant differences were found [59,51]. To perform a
parathyroidectomy in the early post-transplant phase, when
the highest steroid doses are administered and the protec-
tive effect of parathyroid hormone on osteoclasts is most
needed, is problematic. Likewise, since no definite conclu-
sions on the long-term effects of a decrease in renal graft
function observed after parathyroidectomy can be drawn,
it seems sensible to delay a parathyroidectomy until the
spontaneous normalization of persistently high parathyroid
hormone levels appears to be rather unlikely.
Use of calcimimetics
The use of cinacalcet has been investigated most exten-
sively in patients on dialysis. The study results consistently
showed a decrease in parathyroid hormone levels and, ret-
rospectively, analysed a reduction in fracture risk and the
number of hospital stays due to cardiovascular complica-
tions [60,61].
The therapeutic use of cinacalcet in renal transplant re-
cipients with persistent hyperparathyroidism has been eval-
uated in a number of smaller studies (Table 3).
The studies mentioned above show that in renal trans-
plant recipients, the use of cinacalcet to lower PTH levels
also leads to a decrease in calcium concentration and an in-
crease in phosphate concentration. Similar to the situation
after parathyroidectomy, four of the five studies described
a decrease in transplant function but this reduction is mild.
In contrast, a single case study reports that despite high
doses of cinacalcet of up to 180 mg/day and a decrease in
parathyroid hormone concentration from 607 pg/ml to 314
pg/ml, no change in persistent hypercalcaemia occurred.
Apart from initiating cinacalcet therapy after transplanta-
tion, there is the question of whether this therapy should be
continued in patients on haemodialysis prior to renal trans-
plantation. What are the consequences of a pre-operative
discontinuation of cinacalcet therapy prior to transplanta-
tion? Pharmacokinetic data on cinacalcet reveal that the
maximum serum concentration is reached ∼3–5 h after
oral administration. With a half-life of approximately 24 h,
a steady state of cinacalcet serum concentration is achieved
after 4 days [62]. According to the pharmacokinetic data,
parathyroid hormone serum concentration reaches its low-
est level ∼4–6 h after a single dose of cinacalcet, increases
in the subsequent 4–6 h and then stabilizes on a plateau
below the baseline concentration for the next 24 h [63].
Upon discontinuing cinacalcet therapy, serum parathyroid
hormone concentration increases as cinacalcet serum con-
centration decreases and finally settles, within a few days
or weeks, at the original level that was found prior to treat-
ment. In addition, hyperparathyroidism becomes clinically
apparent during hypercalcaemic episodes [64,65]. To avoid
the recurrence of hyperparathyroidism immediately after
transplantation, therapywith cinacalcet should be continued
after intervention. A pharmacokinetic interaction between
cinacalcet and immunosuppressive agents appears to be un-
likely. Although cinacalcet interacts with CYP1A2, 2D6,
3A4 when metabolized and inhibits CYP2D6, clinically
relevant interactions with the standard immunosuppressive
drugs cyclosporine, tacrolimus, sirolimus and everolimus
have not been reported [66]. Consequently, the use of
cinacalcet appears to be a very interesting option for the
de novo treatment of hyperparathyroidism after renal trans-
plantation or for the continuation of treatment started dur-
ing haemodialysis. How many patients require permanent
cinacalcet therapy, and in how many patients the normal-
ization of elevated parathyroid hormone levels occurs at
a later stage has yet to be established. At least in some
patients, it is possible to gradually reduce cinacalcet and
eventually discontinue it altogether at a later time point
without the recurrence of hyperparathyroidism [67]. Nev-
ertheless, therapy with cinacalcet should be initiated using
low doses because hypocalcaemic episodes may be associ-
ated with this therapeutic regimen, especially if a hungry
bone syndrome develops.
Summary
Bone disease after renal transplantation requires preven-
tive therapies to reduce high fracture rates as well as to
assuage other conditions associated with the disturbance
of calcium–phosphate metabolism. The bone disease that
develops with renal insufficiency is aggravated after re-
nal transplantation by a number of factors, including im-
munosuppressive therapy, especially a high-dose steroid
regimen, hypophosphataemia and persistent hyperparathy-
roidism. The administration of vitamin D and calcium is
effective in preventing post-transplant bone density loss.
This also applies to therapies with bisphosphonates, which
are indicated in patients with a high fracture risk. How-
ever, the use of vitamin D and calcium is limited by hy-
percalcaemic episodes and hyperparathyroidism in many
cases. The development of adynamic bone is a risk factor
associated with bisphosphonate therapy, especially when
parathyroidectomy cannot be avoided. Treatment of hy-
pophosphataemia by oral phosphate administration aggra-
vates hyperphosphaturia and may support the development
of nephrocalcinosis, with a possible negative effect on trans-
plant function. Hyperparathyroidism after transplantation
frequently improves over time, and parathyroid hormone
levels return to normal in a number of cases. However,
this process may take months or even years. For early,
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effective treatment of hyperparathyroidism during the pe-
riod of the most severe bone damage after transplantation
and to take advantage of existing therapeutic options for the
preventive treatment of bone disease, cinacalcet is avail-
able, apart from parathyroidectomy. Preliminary data from
renal transplant recipients show that cinacalcet can lower
parathyroid hormone levels, reduce the frequency of hyper-
calcaemic episodes and improve hyperphosphataemia. The
potency of this substance should be evaluated in larger stud-
ies to lay the foundation for its widespread use among renal
transplant recipients, in de novo therapies after transplan-
tation, or for the continuation of treatment initiated during
haemodialysis. However, the use of cinacalcet for the treat-
ment of hyperparathyroidism after transplantation has not
been approved.
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